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Abstract: Exercise tolerance is an important parameter in patients with COPD and a primary 
goal of treatment is to reduce dyspnea to facilitate physical activities and improve health-related 
quality of life. This review examines the link between expiratory flow limitation and dyspnea 
to explain the rationale for the use of bronchodilators and review the characteristics of differ-
ent types of exercise tests, with specific focus on which tests are likely to show a response to 
bronchodilators. An earlier literature search of studies published up to 1999 assessed the effects 
of bronchodilator therapy on dypsnea and exercise tolerance among patients with COPD. This 
current review examines the clinical evidence published since 1999. Thirty-one randomized 
studies of exercise tolerance associated with short- and long-acting β2-agonists and anticho-
linergics were identified. Evidence for the efficacy of bronchodilators in enhancing exercise 
capacity is often contradictory and possibly depends on the exercise test and study methodology. 
However, further studies should confirm the benefit of long-acting bronchodilators in improving 
spontaneous everyday physical activities.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a substantial healthcare burden 
worldwide.1 In developed countries, COPD is already a leading cause of death (ranked 
fourth in the US) and its prevalence is predicted to increase.2 In addition, the number 
of smokers is rising in many countries (notably among women), leading to an escalat-
ing prevalence of COPD.3,4
COPD is characterized by dyspnea-induced impairment that can significantly 
impair performance of everyday tasks. Hence, a primary goal in the management of 
COPD is to improve dyspnea to facilitate physical activities and, ideally, should be 
obtained whatever the severity of the disease to improve the patient’s health-related 
quality of life (HRQoL).
Exercise testing is an increasingly used outcome measure in assessing COPD 
treatments in lieu of the ability to measure improvement in physical activity itself. 
Indeed, physical activity in COPD or aging patients is correlated with maximal exercise 
capacity determined by an incremental cycle exercise test. Moreover, poor exercise 
capacity in COPD patients is a predictor of mortality,5,6 and hence would be a useful 
measure during clinical practice, though most methods for measuring exercise capacity 
are appropriate for the laboratory. Another important finding from laboratory exercise 
testing is determining the locus of limiting symptom in poor exercise capacity, which International Journal of COPD 2010:5 58
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is frequently, but not exclusively, due to dyspnea7,8; however, 
many patients also show a degree of muscle fatigue that 
highlights the importance of conditioning through exercise 
for patients with COPD.
Bronchodilation is a key therapy in COPD, aimed at 
alleviating bronchial obstruction and airflow limitation. 
Guidelines recommend bronchodilators as first-line main-
tenance therapy for patients with all severities of disease.9,10 
Yet, despite the efficacy of bronchodilators in improving 
both bronchial obstruction and pulmonary distension at 
rest, evidence for their beneficial effect on exercise capac-
ity is inconsistent.11,12 In a systematic review on the effects 
of bronchodilators on exercise capacity, Liesker et al11 
reported that a significant improvement in exercise toler-
ance was observed in only half of the studies. Since 1999, 
numerous additional studies have investigated the effects 
of bronchodilators on exercise capacity, including studies 
with once-daily bronchodilators, such as the anticholinergic 
tiotropium and the β2-agonist indacaterol, which had not 
previously been reviewed. In addition, there have been some 
advances in our understanding of the mechanisms by which 
bronchodilators can improve exercise capacity and toler-
ance, and which exercise tests are likely to show a response 
to bronchodilators.
This review aims to examine the clinical evidence pub-
lished since 1999 on the effect of bronchodilators on exercise 
tolerance among patients with COPD, and to review the 
characteristics and clinical significance of exercise tests. 
First, the link between expiratory flow limitation and dyspnea 
is examined to explain the rationale for using bronchodila-
tors and the advantages of improved airflow in relation to 
exercise tolerance.
Selection of studies for review
Literature on the impact of short- and long-acting broncho-
dialtors on exercise tolerance in patients with COPD was 
reviewed by performing a PubMed database search, using the 
search terms “exercise”, “COPD”, “pulmonary disease” and 
the drug scientific name. The search was limited to articles 
published in English between 1999 and 2009, reporting on 
studies of adult (19 years) patients. Studies in asthma were 
excluded. A total of 14 studies of short-acting bronchodila-
tors (salbutamol, procaterol, ipratropium and oxitropium) 
and 22 studies of long-acting bronchodilators (salmeterol, 
formoterol and tiotropium) were identified. At the time of 
writing, no published studies with indacaterol were found 
to include exercise testing.
Air trapping and exercise 
pulmonary hyperinflation – the link 
from expiratory flow limitation  
to daily-living dyspnea
Expiratory flow limitation (EFL) is the primary physiological 
hallmark of COPD, and the most prominent and distressing 
symptom is dyspnea. The relationship between EFL and 
the ability to perform day-to-day activities is complex; for 
example, forced expiratory volume in 1 second (FEV1) is 
important for the diagnosis and monitoring of COPD,6 but 
clinically relevant improvements in symptoms can occur 
in the absence of significant changes in FEV1, and vice 
versa.13,14
A physiological link between EFL and patient-centered 
outcomes may be air trapping and resultant hyperinflation. 
Spirometric indices of hyperinflation, such as inspiratory 
capacity (IC), correlate more closely with improvements in 
dyspnea and exercise tolerance than changes in FEV1.13–15 
Hence, air trapping resulting from EFL, rather than EFL per 
se, may be the significant contributor to dyspnea and exercise 
limitation in COPD.16,17
Air trapping can occur due to both static and dynamic 
hyperinflation processes. Static air trapping can occur 
due to the emphysema and other structural changes in the 
lung that causes the lung to be capable of expelling less 
air. Dynamic air trapping additionally occurs when there 
is insufficient expiratory time for adequate lung emptying. 
As a result, the volume of air left in the lung at the end 
of expiration is increased and the IC is decreased. It is 
dynamic hyperinflation that is susceptible to manipulation 
with bronchodilator treatment. This process of dynamic 
air trapping is exacerbated during more rapid rates of 
ventilation, such as that which occurs during exercise. 
In COPD patients with a severe EFL, dynamic air trapping 
may even occur at a resting respiratory rate. Air trapping 
may occur gradually or abruptly, depending on the severity 
of EFL and the intensity of the exercise, which can affect 
exercise endurance. For example, if air trapping progresses 
gradually relative to the ventilation rate, patients will 
endure the ensuing dyspnea and exercise for longer than 
if it occurs abruptly. This suggests that air trapping is 
the primary functional limitation on exercise tolerance.16 
Further support for this hypothesis is provided by the fact 
that improvements in dynamic air trapping correlate highly 
with reductions in dyspnea.18
Activity limitation is accelerated through a vicious circle 
that develops as the gradual decline of lung function causes International Journal of COPD 2010:5 59
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dynamic air trapping, which triggers a reduction in exercise 
tolerance due to dyspnea and muscle fatigue.16,19 Dyspnea 
dictates the level of activity undertaken and may discourage 
some patients from participating in physical activities.20,21 
Chronic inactivity results in more rapid muscle fatigue due to 
deconditioning, leading to worsening of disease and further 
deterioration of the patient’s HRQoL.22 Thus, the alleviation 
of exercise dyspnea by the reduction of dynamic air trapping 
and hyperinflation remains the principal goal of treatment.
Clinical exercise testing
Since dyspnea is the primary cause of impaired daily-living 
activities in patients with COPD, it is important to evaluate 
exercise tolerance using clinical testing to determine the 
patient’s level of incapacity and response to treatment. There 
are several types of structured clinical exercise tests rang-
ing from the simple and inexpensive self-paced 6-minute 
or 12-minute walk distance (6MWD/12MWD) test and 
externally-paced shuttle walk test (SWT), to the sophisticated 
and expensive cardiopulmonary exercise test.
The protocols used for exercise tests can be classified 
as constant work rate (CWR) or incremental. In the former, 
the work rate is virtually constant throughout the test; hence, 
the duration of the test can be relatively long compared 
with incremental workload tests, in which the workload 
is increased to volitional exhaustion and maximal or near 
maximal aerobic capacity.
Cardiopulmonary exercise testing (CPET) provides the 
most complete physiological evaluation, including insights 
into the mechanisms of exercise limitation23; however, the 
equipment is expensive and requires regular maintenance and 
calibration. Furthermore, qualified personnel are needed to 
supervise the tests to ensure patient safety.
CPET can be used with both incremental and CWR pro-
tocols and permits the evaluation of submaximal and peak 
exercise responses. Modes of exercise most commonly used 
are the treadmill and cycle ergometer. In respiratory clini-
cal tests, the cycle ergometer is often preferred as it offers 
direct quantification of the work rate, the static upper body 
allows easier collection of blood samples and fewer artifacts 
on the electrocardiogram, and it is often cheaper and safer.24 
A limitation is that local muscle fatigue is more predominant 
with cycle ergometry compared with walking on a tread-
mill.7,12,25 A meta-analysis of clinical trials of respiratory 
rehabilitation in patients with COPD determined a minimum 
clinical important difference (MCID) of 8.3 W (95% CI, 
2.8–16.5) maximum exercise capacity using incremental or 
progressive cycle ergometry (PCE).26 Recently, the MCID 
for CWR on a cycle ergometer has been suggested to be an 
increase in exercise time of approximately 33% of baseline, 
though further validation is required.27 A literature search 
revealed no studies that have determined the MCIDs for 
treadmill CPET.
Flat-course walk-tests are the easiest and most economi-
cal procedures for evaluating exercise capacity, as no special-
ist equipment is required; however, results are dependent on 
the motivation of the patient and the degree of encouragement 
offered. In addition, there exists some uncertainty about 
the interpretation of results, particularly with respect to the 
MCID.28
The 6MWD test differs from the other tests in that it 
is self-paced and dependent on patient characteristics and 
methodology. The American Thoracic Society has developed 
guidelines to standardize the use of the 6MWD test in clini-
cal settings, in particular for the measurement of outcomes 
before and after treatment,29 and an improvement of 54 m 
has been proposed as being clinically important in patients 
with stable COPD.30 A more recent analysis estimated that 
the 6MWD should change by approximately 35 m (or 10% 
from baseline) for patients with moderate-to-severe COPD 
in order to represent a clinically important effect.28 These 
discrepancies in MCID may reflect the variable nature of 
the walk tests but also highlight the need to consider disease 
severity when interpreting treatment changes.
Recent reviews of published studies suggest that the 
6MWD test is less sensitive in discerning an effect of bron-
chodilators than cycle ergometery, though there are correla-
tions in results between the two tests in general. A number 
of factors have been suggested to account for this difference, 
including the short duration of the self-paced, non-maximal 
exercise and the variability between patients. The 6MWD 
test also has a lower correlation to lung function than cycle 
ergometry CPET. Nevertheless, changes in exercise endur-
ance with non-pharmacological interventions have been 
discernable using the 6MWD.
The SWT was designed to overcome the criticism that 
patients are unlikely to extend themselves during self-paced 
timed-walk tests.31 The technique allows objective measure-
ment of subjective performance and reduces the effects that 
frailty and comorbidity may have in elderly patients. The test 
comprises a 10 m course, externally paced by an audiotape, 
which increases at set intervals until volitional exhaustion. 
The SWT is standardized and both incremental and CWR 
exercise tests can be performed.
The outcome parameter for the incremental SWT is the 
distance covered before the patient stops because of dyspnea International Journal of COPD 2010:5 60
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or muscle fatigue and the MCID for the incremental SWT 
has recently been defined as 47.5 m.32 Even though the 
incremental SWT is not an endurance test and is arguably 
less relevant to paced activities of daily living, results do cor-
relate with the 6MWD. As with the 6MWD, the correlation 
between the incremental SWT and lung function is low, but 
changes in dyspnea have greater similarity to incremental 
CPET than to the 6MWD.
The endurance SWT is of considerable interest following 
recent work demonstrating that this CWR test is sufficiently 
sensitive to detect changes with inhaled bronchodilators.7 
Indeed, exercise endurance time with the SWT may be 
more sensitive to change from bronchodilators than cycle 
ergometry, though the reasons for this are unclear. The 
constant walking speed for the endurance SWT is calculated 
as 85% of the maximum sustainable walking speed from 
the incremental SWT. Endurance SWT correlates with 
treadmill testing, though the actual endurance times are 
shorter with SWT and there is no MCID established for the 
endurance SWT.
The performance-based tests described above, although 
providing reliable estimates of exercise capacity, may not 
be suited for primary care due to cost and time constraints. 
In addition, it remains uncertain whether such tests accurately 
reflect performance of daily activities such as stair-
  climbing.33 Other tests used to evaluate functional ability and 
exertion-induced dypsnea include unsupported arm exercise 
tests, such as the sit-to-stand test, step testing and Glittre 
activity daily living [ADL] test.34–38 These tests evaluate 
daily-living activities such as climbing stairs, lifting and car-
rying, bending down and rising from a seated position, and 
are beneficial in that they are less time-consuming, easy to 
implement in the primary care environment, and complement 
conventional exercise tests such as the 6MWD. However, 
additional studies are required to evaluate their validity and 
reproducibility.
Impact of bronchodilators  
on exercise tolerance
Inhaled β2-agonists and anticholinergics currently form the 
main classes of bronchodilators used in the treatment of 
COPD. Although oral theophyllines are still used, the find-
ings of clinical studies suggest that they have little or no 
effect on exercise capacity.11 Moreover, there have been no 
new exercise studies with theophylline since 1999.
The database search identified 31 double-blind, 
typically placebo-controlled studies published since 1999 
that included monotherapy with a bronchodilator (Tables 1 
and 2). These studies are discussed below. When interpreting 
the data, it is important to remember the limitations of 
comparison between the different methodologies and patient 
populations.
Short-acting bronchodilators  
(Table 1)
Short-acting β2-agonists
Several salbutamol studies were performed before 2000 and 
are reviewed in detail by Liesker, 2002.11 In brief, seven 
studies assessing the effect of salbutamol on exercise endur-
ance (using the 6MWD or 12MWD) were reviewed39–45 and 
a significant improvement in endurance, compared with 
placebo, was observed in all but one of the studies. Only one 
of the two 6MWD trials could be assessed for MCID,43 but 
this would achieve MCID according to the 35 m criteria 
proposed by Puhan and colleagues,28 but not according to the 
54 m criteria of Redelmeier and colleagues.30
Since 1999, the impact of the short-acting β2-agonist, 
salbutamol, has been determined in three studies: two using 
cardiopulmonary exercise tests and one using upper limb 
exercises (Table 1).46–48 In each of these studies, salbutamol 
was administered as a single dose, reflecting the fact that its 
most appropriate use is as rescue medication.49
In the two studies using cardiopulmonary tests,46,47 endur-
ance was assessed by CWR cycle exercise. A significant 
increase in endurance time was observed by Oga et al,5 
though this was short of being clinically significant accord-
ing to the criteria of Puente-Maestu and colleagues. Aliverti 
et al47 observed no change in CWR cycling exercise endur-
ance time with salbutamol despite a significant decrease in 
IC, suggesting that salbutamol was efficacious in avoiding 
dynamic hyperinflation during the exercise, but this did 
not affect endurance time. In the study by Porto et al,48 
a significant decrease in IC was observed after performing 
an incremental arm exercise test following inhalation with 
placebo; however, no change was observed following inhala-
tion with salbutamol, suggesting again that the bronchodilator 
prevented hyperinflation development.
More recently, two studies50,51 have evaluated the impact 
of procaterol on exercise performance. Shioya et al50 dem-
onstrated clinically significant improvements in walking 
distance using the 6MWD (42 m, P  0.05) together with 
significant improvements in dysnpea and FEV1. In the 
study by Sukisaki and colleagues,51 statistically significant 
improvements in the incremental SWT (37 m, P  0.001) 
were reported, despite no significant improvements in FEV1, 
though this distance is below the MCID.International Journal of COPD 2010:5 61
Exercise tolerance in COPD  Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
T
a
b
l
e
 
1
 
I
m
p
a
c
t
 
o
f
 
s
h
o
r
t
-
a
c
t
i
n
g
 
b
r
o
n
c
h
o
d
i
l
a
t
o
r
s
 
o
n
 
e
x
e
r
c
i
s
e
 
c
a
p
a
c
i
t
y
S
t
u
d
y
 
 
 
D
o
s
e
 
o
f
 
 
s
t
u
d
y
 
d
r
u
g
 
 
S
t
u
d
y
 
 
d
e
s
i
g
n
 
 
N
 
 
 
B
a
s
e
l
i
n
e
 
F
E
V
1
 
(
%
 
p
r
e
d
.
)
 
 
C
h
a
n
g
e
 
i
n
 
 
r
e
s
t
i
n
g
 
l
u
n
g
 
 
v
o
l
u
m
e
 
C
h
a
n
g
e
 
i
n
 
e
x
e
r
c
i
s
e
 
 
 
d
y
s
p
n
e
a
 
 
(
B
o
r
g
 
s
c
o
r
e
)
C
h
a
n
g
e
s
 
i
n
 
e
x
e
r
c
i
s
e
 
p
e
r
f
o
r
m
a
n
c
e
W
a
l
k
i
n
g
 
 
C
W
R
 
c
y
c
l
i
n
g
 
 
P
r
o
g
r
e
s
s
i
v
e
 
c
y
c
l
i
n
g
 
O
t
h
e
r
 
 
S
h
o
r
t
-
a
c
t
i
n
g
 
β
2
-
a
g
o
n
i
s
t
s
S
a
l
b
u
t
a
m
o
l
P
o
r
t
o
 
e
t
 
a
l
4
8
4
0
0
 
µ
g
S
i
n
g
l
e
-
d
o
s
e
,
 
r
a
n
d
o
m
i
z
e
d
1
6
4
1
%
∆
 
I
C
 
P
 
=
 
0
.
0
0
1
a
–
–
–
–
I
n
c
r
e
m
e
n
t
a
l
 
A
r
m
 
 
E
x
e
r
c
i
s
e
:
 
∆
 
I
C
,
 
N
S
b
A
l
i
v
e
r
t
i
 
e
t
 
a
l
4
7
5
 
m
g
 
n
e
b
u
l
i
z
e
d
S
i
n
g
l
e
-
d
o
s
e
,
 
c
r
o
s
s
o
v
e
r
1
8
4
0
.
6
%
∆
 
F
E
V
1
 
P
 

 
0
.
0
0
1
a
 
∆
 
F
R
C
 
P
 

 
0
.
0
1
a
 
∆
 
I
C
 
P
 

 
0
.
0
0
1
a
 
N
S
a
–
N
S
a
–
–
O
g
a
 
e
t
 
a
l
4
6
4
0
0
 
µ
g
S
i
n
g
l
e
-
d
o
s
e
,
 
c
r
o
s
s
o
v
e
r
6
7
4
4
.
2
%
∆
 
F
E
V
1
 
P
 

 
0
.
0
0
1
a
∆
 
F
V
C
 
P
 

 
0
.
0
0
1
a
P
 

 
0
.
0
0
1
a
–
∆
 
e
n
d
u
r
a
n
c
e
 
t
i
m
e
 
2
9
 
s
 
(
+
1
5
%
)
 
 
P
 

 
0
.
0
0
1
a
–
–
P
r
o
c
a
t
e
r
o
l
S
h
i
o
y
a
 
e
t
 
a
l
5
0
2
0
 
µ
g
 
q
i
d
5
2
-
w
e
e
k
,
 
 
r
a
n
d
o
m
i
z
e
d
2
0
4
8
.
1
%
∆
 
F
E
V
1
 
P
 

 
0
.
0
5
b
 
∆
 
F
V
C
 
P
 

 
0
.
0
5
b
 
P
 

 
0
.
0
5
b
6
M
W
D
:
 
∆
 
4
2
 
m
 
(
+
1
0
%
)
 
P
 

 
0
.
0
5
b
–
–
–
S
u
k
i
s
a
k
i
 
e
t
 
a
l
5
1
2
0
 
µ
g
S
i
n
g
l
e
-
d
o
s
e
,
 
c
r
o
s
s
o
v
e
r
1
9
3
8
.
5
%
∆
 
F
E
V
1
 
N
S
a
N
S
b
S
W
T
:
 
∆
 
3
7
 
m
 
(
P
 
=
 
0
.
0
0
1
b
)
–
–
–
S
h
o
r
t
-
a
c
t
i
n
g
 
a
n
t
i
c
h
o
l
i
n
e
r
g
i
c
s
I
p
r
a
t
r
o
p
i
u
m
O
’
D
o
n
n
e
l
l
 
 
e
t
 
a
l
5
7
5
0
0
 
µ
g
 
 
n
e
b
u
l
i
z
e
d
S
i
n
g
l
e
-
d
o
s
e
,
 
c
r
o
s
s
o
v
e
r
1
6
9
0
%
∆
 
F
E
V
1
 
P
 

 
0
.
0
5
a
∆
 
F
V
C
 
P
 

 
0
.
0
5
a
∆
 
T
L
C
 
N
S
a
∆
 
F
R
C
 
P
 

 
0
.
0
5
a
∆
 
I
C
 
N
S
a
N
S
a
–
N
S
a
–
–
P
e
p
i
n
 
e
t
 
a
l
5
6
5
0
0
 
µ
g
 
 
 
n
e
b
u
l
i
z
e
d
S
i
n
g
l
e
-
d
o
s
e
,
 
c
r
o
s
s
o
v
e
r
1
4
5
0
%
∆
 
F
E
V
1
 
P
 

 
0
.
0
0
1
a
–
S
W
T
:
 
∆
 
1
4
4
 
m
 
(
P
 
=
 
0
.
0
3
)
 
6
M
W
D
:
 
N
S
–
–
–
P
e
p
i
n
 
e
t
 
a
l
7
5
0
0
 
µ
g
 
 
n
e
b
u
l
i
z
e
d
S
i
n
g
l
e
-
d
o
s
e
,
 
c
r
o
s
s
o
v
e
r
1
7
5
6
%
W
a
l
k
 
a
n
d
 
C
y
c
l
e
:
 
∆
 
F
E
V
1
 
P
 

 
0
.
0
0
1
a
N
S
S
W
T
:
 
∆
 
e
n
d
u
r
a
n
c
e
 
 
t
i
m
e
 
2
 
m
i
n
s
 
4
4
 
s
 
 
(
P
 

 
0
.
0
1
a
)
N
S
a
–
–
A
k
k
o
c
a
 
e
t
 
a
l
5
5
4
0
 
µ
g
 
q
i
d
2
 
w
e
e
k
,
 
c
r
o
s
s
-
o
v
e
r
1
0
6
9
%
∆
 
F
E
V
1
 
N
S
b
∆
 
F
V
C
 
N
S
b
∆
 
T
L
C
 
N
S
b
 
∆
 
F
R
C
 
N
S
b
 
 
∆
 
I
C
 
N
S
b
–
–
–
∆
 
W
 
m
a
x
 
=
 
N
S
b
∆
 
e
n
d
u
r
a
n
c
e
 
t
i
m
e
 
1
 
m
i
n
 
1
8
 
s
 
 
P
 

 
0
.
0
5
b
–
(
C
o
n
t
i
n
u
e
d
)International Journal of COPD 2010:5 62
Aguilaniu Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
T
a
b
l
e
 
1
 
(
C
o
n
t
i
n
u
e
d
)
S
t
u
d
y
 
 
 
D
o
s
e
 
o
f
 
 
s
t
u
d
y
 
d
r
u
g
 
 
S
t
u
d
y
 
 
d
e
s
i
g
n
 
 
N
 
 
 
B
a
s
e
l
i
n
e
 
F
E
V
1
 
(
%
 
p
r
e
d
.
)
 
 
C
h
a
n
g
e
 
i
n
 
 
r
e
s
t
i
n
g
 
l
u
n
g
 
 
v
o
l
u
m
e
 
C
h
a
n
g
e
 
i
n
 
e
x
e
r
c
i
s
e
 
 
 
d
y
s
p
n
e
a
 
 
(
B
o
r
g
 
s
c
o
r
e
)
C
h
a
n
g
e
s
 
i
n
 
e
x
e
r
c
i
s
e
 
p
e
r
f
o
r
m
a
n
c
e
W
a
l
k
i
n
g
 
 
C
W
R
 
c
y
c
l
i
n
g
 
 
P
r
o
g
r
e
s
s
i
v
e
 
c
y
c
l
i
n
g
 
O
t
h
e
r
 
 
S
a
e
y
 
e
t
 
a
l
1
2
5
0
0
 
µ
g
 
 
n
e
b
u
l
i
z
e
d
S
i
n
g
l
e
-
d
o
s
e
1
8
3
8
%
∆
 
F
E
V
1
 
P
 

 
0
.
0
5
a
,
b
 
 
∆
 
I
V
C
 
P
 

 
0
.
0
0
0
1
a
 
 
∆
 
F
R
C
 
P
 

 
0
.
0
1
a
 
∆
 
R
V
 
P
 

 
0
.
0
0
1
a
–
–
∆
 
e
n
d
u
r
a
n
c
e
 
t
i
m
e
 
1
 
m
i
n
 
5
8
 
s
 
(
+
3
7
%
)
 
P
 
=
 
0
.
0
6
a
–
–
O
g
a
 
e
t
 
a
l
4
6
8
0
 
µ
g
S
i
n
g
l
e
-
d
o
s
e
,
 
c
r
o
s
s
o
v
e
r
6
7
4
4
.
2
%
∆
 
F
E
V
1
 
P
 

 
0
.
0
0
1
a
 
 
∆
 
F
V
C
 
P
 

 
0
.
0
0
1
a
P
 

 
0
.
0
0
1
a
–
∆
 
e
n
d
u
r
a
n
c
e
 
t
i
m
e
 
2
7
 
s
 
(
+
1
4
%
)
 
 
P
 

 
0
.
0
0
1
a
–
–
L
i
e
s
k
e
r
 
e
t
 
a
l
5
3
8
0
 
µ
g
 
t
i
d
1
 
w
e
e
k
,
 
c
r
o
s
s
-
o
v
e
r
3
4
5
5
.
6
%
∆
 
F
E
V
1
 
P
 

 
0
.
0
0
0
1
a
 
 
∆
 
I
V
C
 
P
 

 
0
.
0
0
0
1
a
 
 
∆
 
F
V
C
 
N
S
a
 
∆
 
F
R
C
 
P
 

 
0
.
0
1
a
 
∆
 
R
V
 
P
 

 
0
.
0
0
1
a
N
S
a
–
–
∆
 
e
n
d
u
r
a
n
c
e
 
 
t
i
m
e
 
4
6
 
s
 
 
P
 

 
0
.
0
0
0
1
a
–
W
a
d
b
o
 
e
t
 
a
l
5
4
8
0
 
µ
g
 
t
i
d
1
2
 
w
e
e
k
s
,
 
p
a
r
a
l
l
e
l
1
8
3
3
3
.
6
%
∆
 
F
E
V
1
 
P
 

 
0
.
0
5
a
 
∆
 
F
V
C
 
P
 

 
0
.
0
5
a
 
N
S
a
S
W
T
:
 
N
S
a
–
–
–
R
e
n
n
a
r
d
 
e
t
 
a
l
5
2
3
6
 
µ
g
 
q
i
d
1
2
 
w
e
e
k
s
,
 
p
a
r
a
l
l
e
l
4
0
5
–
∆
 
F
E
V
1
 
P
 

 
0
.
0
5
a
 
 
∆
 
F
V
C
 
P
 

 
0
.
0
5
a
N
S
a
6
M
W
D
:
 
N
S
a
–
–
–
O
x
i
t
r
o
p
i
u
m
S
h
i
o
y
a
 
e
t
 
a
l
5
0
2
0
0
 
µ
g
 
q
i
d
5
2
-
w
e
e
k
,
 
 
r
a
n
d
o
m
i
z
e
d
2
0
4
9
.
4
%
∆
 
F
E
V
1
 
N
S
b
 
 
∆
 
F
V
C
 
N
S
b
N
S
b
6
M
W
D
:
 
N
S
b
–
–
–
O
g
a
 
e
t
 
a
l
5
8
 
 
4
0
0
 
µ
g
 
 
S
i
n
g
l
e
-
d
o
s
e
,
 
c
r
o
s
s
o
v
e
r
 
3
8
 
 
4
0
.
8
%
 
 
∆
 
F
E
V
1
 
P
 

 
0
.
0
0
1
a
 
 
∆
 
F
V
C
 
P
 

 
0
.
0
1
a
 
∆
 
0
.
2
 
P
 

 
0
.
0
5
a
 
(
P
C
E
 
t
e
s
t
 
o
n
l
y
)
 
6
M
W
D
:
 
∆
 
6
 
m
 
 
(
+
1
%
)
 
P
 

 
0
.
0
5
a
 
∆
 
e
n
d
u
r
a
n
c
e
 
t
i
m
e
 
3
4
 
s
 
(
+
1
8
%
)
 
 
P
 

 
0
.
0
0
1
a
∆
 
W
m
a
x
 
3
 
W
 
P
 

 
0
.
0
1
a
 
–
 
 
a
A
c
t
i
v
e
 
d
r
u
g
 
v
e
r
s
u
s
 
p
l
a
c
e
b
o
;
 
b
A
c
t
i
v
e
 
d
r
u
g
 
v
e
r
s
u
s
 
b
a
s
e
l
i
n
e
.
A
b
b
r
e
v
i
a
t
i
o
n
s
:
 
F
E
V
1
,
 
f
o
r
c
e
d
 
e
x
p
i
r
a
t
o
r
y
 
v
o
l
u
m
e
 
i
n
 
1
 
s
e
c
o
n
d
;
 
F
R
C
,
 
f
o
r
c
e
d
 
r
e
s
i
d
u
a
l
 
c
a
p
a
c
i
t
y
;
 
I
C
,
 
i
n
s
p
i
r
a
t
o
r
y
 
c
a
p
a
c
i
t
y
;
 
F
V
C
 
f
o
r
c
e
d
 
v
i
t
a
l
 
c
a
p
a
c
i
t
y
;
 
C
W
R
,
 
c
o
n
s
t
a
n
t
 
w
o
r
k
 
r
a
t
e
;
 
P
C
E
,
 
p
r
o
g
r
e
s
s
i
v
e
 
c
y
c
l
e
 
e
r
g
o
m
e
t
r
y
;
 
C
W
R
,
 
c
o
n
s
t
a
n
t
 
w
o
r
k
 
r
a
t
e
;
 
 
6
M
W
D
,
 
6
 
m
i
n
u
t
e
 
w
a
l
k
 
d
i
s
t
a
n
c
e
;
 
S
W
T
,
 
s
h
u
t
t
l
e
 
w
a
l
k
 
t
e
s
t
;
 
N
S
,
 
n
o
t
 
s
i
g
n
i
fi
c
a
n
t
.International Journal of COPD 2010:5 63
Exercise tolerance in COPD  Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
(
C
o
n
t
i
n
u
e
d
)
T
a
b
l
e
 
2
 
I
m
p
a
c
t
 
o
f
 
l
o
n
g
-
a
c
t
i
n
g
 
b
r
o
n
c
h
o
d
i
l
a
t
o
r
s
 
o
n
 
e
x
e
r
c
i
s
e
 
c
a
p
a
c
i
t
y
S
t
u
d
y
 
 
 
 
D
o
s
e
 
 
o
f
 
d
r
u
g
 
 
 
S
t
u
d
y
 
d
e
s
i
g
n
 
 
 
 
N
 
 
 
 
B
a
s
e
l
i
n
e
 
F
E
V
1
 
 
(
%
 
p
r
e
d
.
)
 
 
 
C
h
a
n
g
e
 
i
n
 
 
r
e
s
t
i
n
g
 
l
u
n
g
 
v
o
l
u
m
e
 
 
C
h
a
n
g
e
 
i
n
 
e
x
e
r
c
i
s
e
 
d
y
s
p
n
e
a
C
h
a
n
g
e
s
 
i
n
 
e
x
e
r
c
i
s
e
 
p
e
r
f
o
r
m
a
n
c
e
 
B
o
r
g
 
s
c
o
r
e
 
 
C
R
Q
 
o
r
 
 
T
D
I
/
B
D
I
 
 
s
c
o
r
e
W
a
l
k
i
n
g
 
 
C
W
R
 
 
c
y
c
l
i
n
g
 
P
r
o
g
r
e
s
s
i
v
e
 
c
y
c
l
i
n
g
 
L
o
n
g
-
a
c
t
i
n
g
 
β
2
-
a
g
o
n
i
s
t
s
S
a
l
m
e
t
e
r
o
l
B
r
o
u
i
l
l
a
r
d
 
e
t
 
a
l
7
7
5
0
 
µ
g
S
i
n
g
l
e
 
d
o
s
e
,
 
5
-
v
i
s
i
t
 
(

4
8
 
h
,
 

4
 
d
a
y
s
 
a
p
a
r
t
)
,
 
c
r
o
s
s
o
v
e
r
2
0
5
2
%
∆
 
F
E
V
1
 
P
 

 
0
.
0
0
0
1
a
 
 
∆
 
F
V
C
 
P
 

 
0
.
0
0
0
1
a
 
 
∆
 
I
C
 
N
S
a
 
 
∆
 
F
R
C
 
N
S
a
 
 
∆
 
R
V
 
P
 

 
0
.
0
5
a
∆
 
B
o
r
g
 
s
c
o
r
e
 
 
5
.
6
 
P
 
=
 
0
.
0
0
6
a
 
 
(
I
s
o
t
i
m
e
)
–
S
W
T
:
 
∆
 
1
6
0
 
m
 
 
P
 
=
 
0
.
0
2
a
 
 
∆
 
e
n
d
u
r
a
n
c
e
 
 
t
i
m
e
 
1
 
m
i
n
 
5
7
 
s
 
 
P
 
=
 
0
.
0
2
a
–
–
S
t
o
c
k
l
e
y
 
e
t
 
a
l
7
6
5
0
 
µ
g
 
b
i
d
1
2
-
m
o
n
t
h
,
 
p
a
r
a
l
l
e
l
4
2
6
4
6
.
1
%
∆
 
F
E
V
1
 
P
 

 
0
.
0
0
0
1
a
 
 
∆
 
F
V
C
 
P
 

 
0
.
0
1
a
 
 
∆
 
S
V
C
 
P
 

 
0
.
0
5
a
 
 
∆
 
I
C
 
P
 

 
0
.
0
5
a
N
S
a
–
S
W
T
:
 
∆
 
3
0
 
m
 
 
P
 
=
 
0
.
0
4
a
–
–
O
’
D
o
n
n
e
l
l
 
e
t
 
a
l
7
5
5
0
 
µ
g
 
b
i
d
8
-
w
e
e
k
,
 
p
a
r
a
l
l
e
l
1
2
3
3
9
.
5
%
∆
 
F
E
V
1
 
P
 

 
0
.
0
5
a
 
 
∆
 
F
V
C
 
P
 

 
0
.
0
5
a
 
 
∆
 
F
R
C
 
P
 

 
0
.
0
5
a
 
 
∆
 
R
V
 
P
 

 
0
.
0
5
a
 
 
∆
 
I
C
 
P
 

 
0
.
0
5
a
N
S
a
–
–
N
S
a
–
M
a
n
 
e
t
 
a
l
7
4
5
0
 
µ
g
 
b
i
d
2
-
w
e
e
k
,
 
c
r
o
s
s
o
v
e
r
1
6
3
1
.
1
%
∆
 
F
E
V
1
 
N
S
a
 
 
∆
 
V
C
 
N
S
a
 
 
∆
 
I
C
 
P
 

 
0
.
0
5
a
 
 
∆
 
R
V
 
N
S
a
∆
 
B
o
r
g
 
s
c
o
r
e
 
 
0
.
8
4
 
(
P
 
=
 
0
.
0
2
a
)
 
(
I
s
o
t
i
m
e
)
–
T
r
e
a
d
m
i
l
l
 
 
e
n
d
u
r
a
n
c
e
 
 
t
e
s
t
:
 
N
S
a
–
–
O
’
D
o
n
n
e
l
l
 
 
e
t
 
a
l
7
3
5
0
 
µ
g
 
b
i
d
2
-
w
e
e
k
,
 
c
r
o
s
s
o
v
e
r
2
3
4
2
%
∆
 
F
E
V
1
 
P
 

 
0
.
0
1
a
 
 
∆
 
F
V
C
 
P
 

 
0
.
0
1
a
 
 
∆
 
F
R
C
 
P
 

 
0
.
0
1
a
 
 
∆
 
R
V
 
P
 

 
0
.
0
1
a
 
 
∆
 
I
C
 
P
 

 
0
.
0
1
a
N
S
a
–
–
∆
 
e
n
d
u
r
a
n
c
e
 
 
t
i
m
e
 
1
 
m
i
n
 
3
6
 
s
 
(
+
5
8
%
)
 
 
P
 
=
 
0
.
0
1
8
a
–
G
u
p
t
a
 
e
t
 
a
l
7
2
5
0
 
µ
g
 
b
i
d
8
-
w
e
e
k
,
 
p
a
r
a
l
l
e
l
3
3
–
∆
 
F
E
V
1
 
P
 

 
0
.
0
5
b
 
 
∆
 
F
V
C
 
P
 

 
0
.
0
5
b
–
T
D
I
:
 
P
 

 
0
.
0
1
a
6
M
W
D
:
 
N
S
a
–
–
R
e
n
n
a
r
d
 
e
t
 
a
l
5
2
4
2
 
µ
g
 
b
i
d
1
2
-
w
e
e
k
,
 
p
a
r
a
l
l
e
l
4
0
5
–
∆
 
F
E
V
1
 
P
 

 
0
.
0
5
a
 
 
∆
 
F
V
C
 
P
 

 
0
.
0
5
a
N
S
a
–
6
M
W
D
:
 
N
S
a
–
–
W
e
i
n
e
r
 
e
t
 
a
l
7
1
5
0
 
µ
g
 
b
i
d
1
8
-
w
e
e
k
,
 
p
a
r
a
l
l
e
l
2
3
3
3
%
∆
 
F
E
V
1
 
N
S
b
N
S
b
–
6
M
W
D
 
N
S
b
–
–
5
0
 
µ
g
 
b
i
d
+
 
e
x
e
r
c
i
s
e
1
7
3
5
%
N
S
b
6
M
W
D
:
 
∆
 
4
2
 
m
 
(
+
1
7
%
)
 
P
 

 
0
.
0
5
bInternational Journal of COPD 2010:5 64
Aguilaniu Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
T
a
b
l
e
 
2
 
(
C
o
n
t
i
n
u
e
d
)
S
t
u
d
y
 
 
 
 
D
o
s
e
 
 
o
f
 
d
r
u
g
 
 
 
S
t
u
d
y
 
d
e
s
i
g
n
 
 
 
 
N
 
 
 
 
B
a
s
e
l
i
n
e
 
F
E
V
1
 
 
(
%
 
p
r
e
d
.
)
 
 
 
C
h
a
n
g
e
 
i
n
 
 
r
e
s
t
i
n
g
 
l
u
n
g
 
v
o
l
u
m
e
 
 
C
h
a
n
g
e
 
i
n
 
e
x
e
r
c
i
s
e
 
d
y
s
p
n
e
a
C
h
a
n
g
e
s
 
i
n
 
e
x
e
r
c
i
s
e
 
p
e
r
f
o
r
m
a
n
c
e
 
B
o
r
g
 
s
c
o
r
e
 
 
C
R
Q
 
o
r
 
 
T
D
I
/
B
D
I
 
 
s
c
o
r
e
W
a
l
k
i
n
g
 
 
C
W
R
 
 
c
y
c
l
i
n
g
 
P
r
o
g
r
e
s
s
i
v
e
 
c
y
c
l
i
n
g
 
5
0
 
µ
g
 
b
i
d
 
+
 
 
e
x
e
r
c
i
s
e
 
+
 
i
n
s
p
i
r
a
t
o
r
y
 
m
u
s
c
l
e
 
 
t
r
a
i
n
i
n
g
1
1
3
5
%
P
 

 
0
.
0
1
b
6
M
W
D
:
 
∆
 
5
0
 
m
 
 
(
+
2
0
%
)
 
P
 

 
0
.
0
5
b
F
o
r
m
o
t
e
r
o
l
C
a
z
z
o
l
a
 
e
t
 
a
l
7
0
1
2
 
µ
g
 
b
i
d
5
-
d
a
y
,
 
c
r
o
s
s
o
v
e
r
2
2
1
4
%
–
5
6
%
∆
 
F
E
V
1
 
P
 

 
0
.
0
5
b
 
 
∆
 
I
C
 
P
 

 
0
.
0
5
b
∆
 
B
o
r
g
 
s
c
o
r
e
 
 
–
1
.
7
 
P
 
=
 
0
.
0
0
5
b
 
 
(
p
r
e
-
l
a
s
t
 
d
o
s
e
)
 
 
–
1
.
8
 
P
 
=
 
0
.
0
0
1
b
 
(
p
o
s
t
-
l
a
s
t
 
d
o
s
e
)
–
6
M
W
D
:
 
∆
 
5
3
.
6
m
 
 
P
 
=
 
0
.
0
0
6
b
 
1
2
M
W
D
:
 
 
∆
 
5
9
.
9
 
m
 
P
 
=
 
0
.
0
1
8
b
–
–
N
e
d
e
r
 
e
t
 
a
l
6
9
1
2
 
µ
g
 
b
i
d
2
-
w
e
e
k
,
 
c
r
o
s
s
o
v
e
r
2
1
3
8
.
8
%
∆
 
I
C
 
P
 

 
0
.
0
5
a
 
 
∆
 
E
E
L
V
 
P
 

 
0
.
0
5
a
 
 
∆
 
R
V
 
P
 

 
0
.
0
5
a
N
S
a
–
–
∆
 
2
 
m
i
n
 
1
0
 
s
 
P
 
=
 
0
.
0
5
2
–
A
k
k
o
c
a
 
e
t
 
a
l
5
5
1
2
 
µ
g
 
b
i
d
2
 
w
e
e
k
,
 
c
r
o
s
s
o
v
e
r
1
0
6
9
%
∆
 
F
E
V
1
 
N
S
 
 
∆
 
F
V
C
 
N
S
 
 
∆
 
F
E
V
1
/
F
V
C
 
P
 

 
0
.
0
5
b
 
∆
 
T
L
C
 
N
S
 
 
∆
 
F
R
C
 
N
S
 
 
∆
 
I
C
 
N
S
–
–
–
–
∆
 
T
T
E
 
4
5
 
s
 
 
P
 

 
0
.
0
5
b
W
a
d
b
o
 
e
t
 
a
l
5
4
1
8
 
µ
g
 
b
i
d
1
2
-
w
e
e
k
,
 
p
a
r
a
l
l
e
l
1
8
3
3
3
.
3
%
∆
 
F
E
V
1
 
P
 

 
0
.
0
5
a
 
 
∆
 
F
V
C
 
P
 

 
0
.
0
5
a
N
S
–
S
W
T
:
 
N
S
–
–
A
a
l
b
e
r
s
 
e
t
 
a
l
6
8
 
4
.
5
 
µ
g
 
b
i
d
 
9
 
µ
g
 
b
i
d
 
1
8
 
µ
g
 
b
i
d
 
1
2
-
w
e
e
k
,
 
p
a
r
a
l
l
e
l
T
o
t
a
l
 
6
9
2
 
1
4
4
 
1
3
6
 
1
5
0
5
4
%
 
5
3
.
1
%
 
5
4
.
4
%
 
5
4
.
7
%
 
∆
 
F
E
V
1
 
P
 

 
0
.
0
1
a
∆
 
F
E
V
1
 
P
 

 
0
.
0
5
a
∆
 
F
E
V
1
 
P
 

 
0
.
0
0
1
a
–
–
S
W
T
:
N
S
a
N
S
a
N
S
a
–
–
L
i
e
s
k
e
r
 
e
t
 
a
l
5
3
4
.
5
 
µ
g
 
b
i
d
1
-
w
e
e
k
,
 
c
r
o
s
s
o
v
e
r
3
4
–
∆
 
F
E
V
1
 
P
 

 
0
.
0
5
a
 
∆
 
F
R
C
 
P
 

 
0
.
0
5
a
 
 
∆
 
F
V
C
 
N
S
a
 
 
∆
 
I
V
C
 
P
 

 
0
.
0
5
a
 
 
∆
 
R
V
 
P
 

 
0
.
0
5
a
N
S
–
–
–
∆
 
T
T
E
 
4
4
 
s
 
 
P
 

 
0
.
0
0
0
1
a
9
 
µ
g
 
b
i
d
3
4
–
∆
 
F
E
V
1
 
P
 

 
0
.
0
5
a
 
 
∆
 
F
R
C
 
P
 

 
0
.
0
5
a
 
 
∆
 
F
V
C
 
N
S
a
 
 
∆
 
I
V
C
 
P
 

 
0
.
0
5
a
 
 
∆
 
R
V
 
P
 

 
0
.
0
5
a
N
S
–
–
–
3
4
 
s
 
P
 

 
0
.
0
1
aInternational Journal of COPD 2010:5 65
Exercise tolerance in COPD  Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
1
8
 
µ
g
 
b
i
d
3
4
–
∆
 
F
E
V
1
 
P
 

 
0
.
0
5
a
 
 
∆
 
F
R
C
 
P
 

 
0
.
0
5
a
 
 
∆
 
F
V
C
 
N
S
a
 
 
∆
 
I
V
C
 
P
 

 
0
.
0
5
a
 
 
∆
 
R
V
 
P
 

 
0
.
0
5
a
N
S
–
–
–
2
3
 
s
 
P
 

 
0
.
0
5
a
L
o
n
g
-
a
c
t
i
n
g
 
A
n
t
i
c
h
o
l
i
n
e
r
g
i
c
s
T
i
o
t
r
o
p
i
u
m
A
m
b
r
o
s
i
n
o
 
e
t
 
a
l
8
3
1
8
 
µ
g
 
q
d
4
-
w
e
e
k
,
 
p
a
r
a
l
l
e
l
1
1
7
4
2
.
5
%
∆
 
F
E
V
1
 
P
 

 
0
.
0
5
–
T
D
I
:
 
N
S
a
6
M
W
D
:
 
N
S
a
–
–
1
8
 
µ
g
 
q
d
 
+
 
r
e
h
a
b
i
l
i
t
a
t
i
o
n
2
5
-
w
e
e
k
 
(
i
n
c
l
u
d
i
n
g
 
8
 
w
e
e
k
s
’
 
r
e
h
a
b
i
l
i
t
a
t
i
o
n
)
,
 
p
a
r
a
l
l
e
l
1
1
7
4
2
.
5
%
∆
 
F
E
V
1
 
P
 

 
0
.
0
5
–
A
t
 
e
n
d
 
o
f
 
P
R
 
(
W
e
e
k
 
1
3
)
:
 
3
.
6
0
 
u
n
i
t
s
 
 
P
 
=
 
0
.
0
0
1
a
 
 
A
t
 
 
W
e
e
k
 
2
5
:
 
N
S
a
W
e
e
k
 
1
3
:
 
N
S
a
 
 
W
e
e
k
 
2
5
:
 
N
S
a
–
–
T
r
a
v
e
r
s
 
e
t
 
a
l
8
2
1
8
 
µ
g
 
q
d
7
–
1
0
 
d
a
y
,
 
c
r
o
s
s
o
v
e
r
1
8
4
0
%
∆
 
F
E
V
1
 
P
 

 
0
.
0
1
a
 
 
∆
 
R
V
 
P
 

 
0
.
0
1
a
 
∆
 
F
R
C
 
P
 

 
0
.
0
1
a
N
S
–
–
N
S
a
–
O
k
u
d
a
n
 
e
t
 
a
l
8
1
1
8
 
µ
g
 
q
d
S
i
n
g
l
e
-
d
o
s
e
,
 
 
c
r
o
s
s
o
v
e
r
4
4
–
–
N
S
–
6
M
W
D
:
 
∆
 
1
4
.
6
 
 
m
 
(
+
4
%
)
 
P
 

 
0
.
0
5
a
–
–
V
e
r
k
i
n
d
r
e
 
e
t
 
a
l
8
0
1
8
 
µ
g
 
q
d
1
2
-
w
e
e
k
,
 
p
a
r
a
l
l
e
l
4
6
3
4
.
7
%
∆
 
F
V
C
 
P
 

 
0
.
0
5
a
 
∆
 
I
C
 
P
 

 
0
.
0
5
a
N
S
a
T
D
I
:
 
N
S
a
S
W
T
:
 
∆
 
3
6
 
m
 
P
 

 
0
.
0
5
a
–
–
C
a
s
a
b
u
r
i
 
e
t
 
a
l
7
9
1
8
 
µ
g
 
q
d
4
-
w
e
e
k
,
 
p
a
r
a
l
l
e
l
5
5
3
4
%
∆
 
F
E
V
1
 
P
 

 
0
.
0
1
a
 
 
∆
 
F
V
C
 
P
 

 
0
.
0
0
1
a
–
T
D
I
:
 
N
S
a
T
r
e
a
d
m
i
l
l
 
e
n
d
u
r
a
n
c
e
 
t
e
s
t
:
 
N
S
a
–
–
1
8
 
µ
g
 
q
d
 
+
 
r
e
h
a
b
i
l
i
t
a
t
i
o
n
2
5
-
w
e
e
k
 
(
8
 
w
e
e
k
s
’
 
r
e
h
a
b
i
l
i
t
a
t
i
o
n
)
 
p
a
r
a
l
l
e
l
5
5
3
4
%
∆
 
F
E
V
1
 
P
 

 
0
.
0
1
a
 
 
∆
 
F
V
C
 
P
 

 
0
.
0
0
1
a
N
S
a
1
.
6
7
 
u
n
i
t
s
 
 
P
 

 
0
.
0
1
a
∆
 
6
 
m
i
n
 
3
6
 
s
 
P
 

 
0
.
0
5
a
–
–
M
a
l
t
a
i
s
 
e
t
 
a
l
7
8
1
8
 
µ
g
 
q
d
6
-
w
e
e
k
,
 
p
a
r
a
l
l
e
l
1
3
1
4
3
.
1
%
∆
 
F
E
V
1
 
P
 

 
0
.
0
0
1
a
 
 
∆
 
F
V
C
 
P
 

 
0
.
0
0
1
a
 
∆
 
S
V
C
 
P
 

 
0
.
0
0
1
a
 
∆
 
I
C
 
P
 

 
0
.
0
0
1
a
 
 
∆
 
F
R
C
 
P
 

 
0
.
0
0
1
a
 
 
∆
 
R
V
 
P
 

 
0
.
0
0
1
a
 
 
∆
 
T
L
C
 
P
 

 
0
.
0
1
a
∆
 
-
1
.
0
5
 
 
P
 

 
0
.
0
0
1
a
 
 
(
I
s
o
t
i
m
e
)
–
–
∆
 
3
 
m
i
n
 
5
4
 
s
 
(
+
4
1
%
)
 
 
P
 

 
0
.
0
0
1
a
–
O
’
D
o
n
n
e
l
l
 
e
t
 
a
l
1
8
 
 
 
 
1
8
 
µ
g
 
q
d
 
 
 
 
6
-
w
e
e
k
,
 
p
a
r
a
l
l
e
l
 
 
 
 
9
6
 
 
 
 
4
2
%
 
 
 
 
∆
 
F
E
V
1
 
P
 

 
0
.
0
0
1
a
 
 
∆
 
F
V
C
 
P
 

 
0
.
0
0
0
1
a
 
∆
 
I
C
 
P
 

 
0
.
0
5
a
 
 
∆
 
R
V
 
P
 

 
0
.
0
0
1
a
 
∆
 
F
R
C
 
P
 

 
0
.
0
0
1
a
∆
 
-
0
.
9
 
 
P
 

 
0
.
0
1
a
 
 
(
I
s
o
t
i
m
e
)
 
 
–
 
 
 
 
–
 
 
 
 
∆
 
1
 
m
i
n
 
4
5
 
s
 
(
+
2
1
%
)
 
 
P
 

 
0
.
0
1
a
 
 
–
 
 
 
 
a
A
c
t
i
v
e
 
d
r
u
g
 
v
e
r
s
u
s
 
p
l
a
c
e
b
o
;
 
b
A
c
t
i
v
e
 
d
r
u
g
 
v
e
r
s
u
s
 
b
a
s
e
l
i
n
e
.
A
b
b
r
e
v
i
a
t
i
o
n
s
:
 
E
E
L
V
,
 
e
n
d
-
e
x
p
i
r
a
t
o
r
y
 
l
u
n
g
 
v
o
l
u
m
e
;
 
F
E
V
1
,
 
f
o
r
c
e
d
 
e
x
p
i
r
a
t
o
r
y
 
v
o
l
u
m
e
 
i
n
 
1
 
s
e
c
o
n
d
;
 
C
R
Q
,
 
c
h
r
o
n
i
c
 
r
e
s
p
i
r
a
t
o
r
y
 
d
i
s
e
a
s
e
 
q
u
e
s
t
i
o
n
n
a
i
r
e
;
 
B
D
I
,
 
b
a
s
e
l
i
n
e
 
d
y
s
p
n
e
a
 
i
n
d
e
x
;
 
T
D
I
,
 
t
r
a
n
s
i
t
i
o
n
 
d
y
s
p
n
e
a
 
i
n
d
e
x
;
 
F
R
C
,
 
f
o
r
c
e
d
 
r
e
s
i
d
u
a
l
 
c
a
p
a
c
i
t
y
;
 
I
C
,
 
i
n
s
p
i
r
a
t
o
r
y
 
c
a
p
a
c
i
t
y
;
 
F
V
C
,
 
f
o
r
c
e
d
 
v
i
t
a
l
 
c
a
p
a
c
i
t
y
;
 
V
C
,
 
v
i
t
a
l
 
c
a
p
a
c
i
t
y
;
 
R
V
,
 
r
e
s
i
d
u
a
l
 
v
o
l
u
m
e
;
 
C
W
R
 
c
o
n
s
t
a
n
t
 
w
o
r
k
 
r
a
t
e
;
 
I
V
C
,
 
i
n
s
p
i
r
a
t
o
r
y
 
v
i
t
a
l
 
c
a
p
a
c
i
t
y
;
 
P
C
E
,
 
p
r
o
g
r
e
s
s
i
v
e
 
c
y
c
l
e
 
e
r
g
o
m
e
t
r
y
;
 
6
M
W
D
,
 
6
 
m
i
n
u
t
e
 
w
a
l
k
 
d
i
s
t
a
n
c
e
;
 
S
W
T
,
 
s
h
u
t
t
l
e
 
w
a
l
k
 
t
e
s
t
;
 
T
T
E
,
 
T
i
m
e
 
t
o
 
e
x
h
a
u
s
t
i
o
n
 
(
f
o
r
 
P
C
E
)
;
 
N
S
,
 
n
o
t
 
s
i
g
n
i
fi
c
a
n
t
;
 
P
R
,
 
p
u
l
m
o
n
a
r
y
 
r
e
h
a
b
i
l
i
t
a
t
i
o
n
.International Journal of COPD 2010:5 66
Aguilaniu Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Short-acting anticholinergics
The effect of short-acting anticholinergics on exercise is 
inconsistent (Table 1).7,12,46,50,52–58 In general, they are recom-
mended for the management of mild COPD and as required 
in symptomatic patients.10,59 Prior to the availability of the 
once-daily anticholinergic, tiotropium, short-acting anti-
cholinergics had been used for chronic treatment across all 
severities of the disease.
Single doses of ipratropium have shown some beneficial 
effect on exercise tolerance.7,46,56 In many of the studies 
using 6MWD, including those reviewed by Liesker et al,11 
the significant results did not reach the MCID proposed 
by Puhan and colleagues.28 MCID responses have been 
reported with the SWT56 and CWR cycling,12 though the 
latter did not achieve statistical significance, but did include 
study patients with more severe COPD than many of the 
other studies.
In longer-term studies involving treatment periods of 
up to 12 weeks,52–55 only Liesker et al53 and Akkoca et al55 
found a significant improvement in exercise performance. 
Ipratropium significantly increased time to exhaustion in the 
incremental cycle exercise used by Liesker et al53 and Akkoca 
et al,55 though the latter small study was not statistically 
  significant with respect to change in work rate.
Two studies examining the effect of oxitropium on 
exercise performance have been published since 1999.50,58 
Oga et al58 observed statistically significant (but not MCID) 
improvements in both the 6MWD (6 m increase, P  0.05) 
and CWR cycle ergometry (34 s increased endurance, 
P  0.001) compared with placebo, following a single dose 
of 400 µg oxitropium. However, in the study by Shioya 
et al,50 6MWD in patients receiving 600 µg oxitropium was 
not shown to differ significantly from baseline after 12, 24 or 
52 weeks of treatment. A total of six oxitropium studies60–65 
were included in the review of Liesker et al,11 and in five of 
these studies60,62–65 a statistically significant improvement in 
exercise performance was observed, though these did not 
achieve a definite MCID.
In two single-dose studies66,67 evaluating the effect of a 
combination of salbutamol and ipratropium, improvements 
in endurance were observed, although statistical significance 
was only observed in that of Cukier et al66 who reported an 
improvement in 6MWD of 21 m (+6%, P  0.05) compared 
with placebo. In comparison, Peters et al67 reported that 
endurance time, using CWR cycle ergometry improved by 
1 min 42 s (+31%) with a salbutamol-ipratropium combina-
tion, although this improvement failed to achieve statistical 
significance versus placebo (P = 0.067).
Long-acting bronchodilators 
(Table 2)
Long-acting β2-agonists
The effects of two long-acting β2-agonists on exercise 
capacity have been evaluated: formoterol53–55,68–70 and 
salmeterol52,71–77 (Table 2).
In a study by Cazzola et al,70 5-day treatment with for-
moterol was shown to increase walking distance by 53.6 m at 
the end of the 6MWD test (achieving MCID) and by 59.9 m at 
the end of the 12MWD test compared with baseline. The per-
ception of breathlessness measured by the Borg scale was also 
significantly reduced with formoterol compared with base-
line. However, in two larger studies,54,68 formoterol treatment 
resulted in no significant improvement in the performance of 
the incremental SWT compared with placebo.
Using PCE to symptom limitation, Liesker et al53 showed 
significant enhancement of time to exhaustion after 1-week 
treatment with formoterol compared with placebo of between 
23 and 44 seconds, as was reported in the previous review. 
Also using PCE, Akkoca et al55 demonstrated a significant 
improvement in time to exhaustion of 45 seconds compared 
with baseline after dosing with formoterol and following 
14 days’ treatment with formoterol. Using CWR cycling in 
patient with more severe COPD than in the previous two 
trials, change in endurance time with 2-week treatment with 
formoterol did not achieve statistical significance compared 
with placebo (Neder et al69).
For salmeterol, Liesker 2002 reviewed three studies 
performed before 2000, all of which did not find a significant 
effect of salmererol on walking distance (6MWD or 12MWD) 
after treatment for up to 12 weeks.11 Similar results have been 
found in three further studies using the 6MWD test since 2000 
that are reported in Table 2, though the perception of dyspnea 
during exercise was significantly reduced in one of these 
studies.52,71,72 One study71 showed significant improvements 
in 6MWD with a combination of salmeterol and 6 weeks of 
general exercise training (16% improvement; P  0.05) or 6 
weeks’ general exercise training plus inspiratory muscle train-
ing (20% improvement; P  0.05). This may suggest an addi-
tive or synergistic effect of salmeterol and exercise training; 
however, this cannot be confirmed due to the study design.
Salmeterol has significantly improved exercise capacity 
measured using the SWT.76,77 In a large 1-year trial, patients 
treated with salmeterol walked a statistically significant 30 
m further in an incremental SWT than patients treated with 
placebo, though the difference was below that considered 
clinically significant and perception of breathlessness was International Journal of COPD 2010:5 67
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not statistically different.76 In a smaller, single-dose study, 
Brouillard et al77 demonstrated statistically significant 
improvements in walking performance with salmeterol com-
pared with placebo measured by both incremental (160 m; 
P  0.05) and endurance SWT (1 min 57 s; P  0.05), with 
the difference in incremental SWT exceeding the MCID. 
Salmeterol also reduced the perception of dyspnea during 
exercise in this study when compared with placebo at an 
isotime, but not at the end of exercise.
O’Donnell et al73 demonstrated a clinically significant 
improvement of exercise endurance with 2-week treatment 
with salmeterol (1 min 36 s, 58% increase above placebo; 
P  0.05) using a CWR cycle exercise test. This improve-
ment in endurance time correlated with increases in IC, 
both at rest and during exercise, supporting the notion that 
hyperinflation has a major impact on exercise tolerance. 
However, a statistically significant difference from placebo 
was not observed in a later, larger CWR cycle exercise test 
trial following 8-week treatment with salmeterol.75 Percep-
tion of dyspnea during exercise with salmeterol did not differ 
from placebo in either of these studies. A significant change 
in endurance time compared with placebo was also not seen 
following 2 weeks of treatment with salmeterol in a study 
using a CWR treadmill exercise test,74 though perception of 
dyspnea during exercise was reduced with salmeterol.
Long-acting anticholinergic: tiotropium
The once-daily anticholinergic, tiotropium, was first intro-
duced for COPD in Europe in 2002 and has become one of 
the most prescribed maintenance treatments. Seven exercise 
studies with tiotropium have been published since 1999 
and were not included in the previous systematic review 
(Table 3).18,78–83 As with other types of bronchodilators,13,73 
tiotropium has shown reductions in parameters of hyperinfla-
tion, and improvements in exercise endurance time correlated 
with IC.18,78,84
As observed with other bronchodilators, use of the 
6MWD to investigate changes in exercise endurance with 
tiotropium has had limited success.81,83 A significant increase 
in the 6MWD (P  0.05) was observed by Okudan et al81 
following administration of a single dose of tiotropium com-
pared with placebo, but this was below the MCID proposed by 
Puhan and colleagues and perception of dyspnea during exer-
cise was not changed.28 However, no significant differences 
were observed in 6MWD or perception of dyspnea following 
4-week treatment with tiotropium compared with placebo in a 
study that continued to investigate pulmonary rehabilitation. 
Compared with placebo, tiotropium significantly increased 
the mean distance walked during the SWT by 36 m (11.8% 
increase; P  0.05) after 12 weeks of treatment in the study 
by Verkindre et al.80 However, this too is below the MCID 
and perception of dyspnea was not different from placebo, 
despite a significant change in lung volumes.
Tiotropium has been reported to significantly increase 
CWR cycle endurance time compared with placebo by 
1 min 45 s (21% increase, P  0.01)18 and by 3 min 54 s 
(41% increase, P  0.001)78 following 6 weeks of daily 
administration in two independent studies. The change in 
endurance time in the second of these studies exceeds the 
MCID proposed by Puente-Maestu and colleagues27 and 
perception of dyspnea during exercise was also significantly 
reduced by tiotropium in both trials. A statistically significant 
difference compared with placebo in CWR endurance time 
improvement and perception of dyspnea was not found in a 
smaller crossover trial by Travers et al.82
Casaburi et al demonstrated that tiotropium amplified 
the effects of pulmonary rehabilitation on CWR treadmill 
endurance,79 which has also been associated with an increase 
in self-reported participation in physical activity.85 Although 
4-week treatment with tiotropium did not significantly 
increase endurance time alone compared with placebo 
(a difference of 1 min 39 s; 15.6% increase), tiotropium 
significantly improved CWR treadmill endurance times 
compared with placebo following an 8-week pulmonary 
rehabilitation programme such that the difference between the 
groups was 6 min 36 s (41.9% increase). In contrast, Ambro-
sino et al83 reported no improvement in 6MWD following 
the addition of tiotropium to pulmonary rehabilitation for 8 
weeks, although significant improvements in dyspnea were 
observed compared with placebo (P  0.01). These seem-
ingly contradictory results may be reflective of the difference 
in sensitivity of the exercise tests used in these trials.
Comparative studies (Table 3)
Five studies46,52–55 directly evaluated the effects of different 
classes of bronchodilators (Table 3). Oga et al46 compared 
the effects of the short-acting β2-agonist salbutamol with 
the short-acting anticholinergic ipratropium on exercise 
capacity using a CWR cycle ergometry test. Improvement 
in FEV1 was significantly greater with salbutamol compared 
with ipratropium, but the magnitudes of improvement in the 
CWR cycle ergometry test were similar with both treatments. 
Four studies52–55 compared the short-acting anticholinergic 
ipratropium with the long-acting β2-agonists salmeterol52 or 
formoterol.53–55 No significant treatment differences between 
ipratropium and formoterol were observed in either the PCE International Journal of COPD 2010:5 68
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test performed by Akkoca et al55 or the SWT performed by 
Wadbo et al.54 A significant difference in favor of ipratro-
pium compared with 18 µg formoterol was found in time to 
exhaustion in the PCE test performed by Liesker et al53; how-
ever, no significant treatment difference was found between 
ipratropium and 4.5 µg or 9 µg formoterol. In the comparison 
between ipratropium and salmeterol by Oga et al,46 no sig-
nificant difference between the two treatments was observed 
in terms of lung function, dyspnea or 6MWD.
As of yet, there are no published studies that have 
compared the effects on exercise capacity of long-acting 
β2-agonists with the long-acting anticholinergic tiotropium.
Conclusions
Evidence for the efficacy of bronchodilators in enhancing the 
exercise capacity of patients with COPD is often contradic-
tory. Some of the inconsistency may be explained by differ-
ences in the mode and duration of action of bronchodilators; 
however, considerable variations may be due to inherent 
differences in study design or patients studied. In particular, 
the method of assessing exercise tolerance is a matter for con-
siderable discussion and requires further investigation before 
we can fully appreciate which bronchodilators consistently 
improve exercise endurance. However, some general points 
can be made from systematic review of the literature.
Short-acting bronchodilators may be an appropriate 
choice for additional bronchodilation when required, but are 
not suitable for use on a day-to-day basis to provide sustained 
bronchodilation and improve HRQoL. Important factors that 
contribute to HRQoL are enhanced symptom control and 
increased exercise capacity. For short-acting bronchodila-
tors, the data suggest that their effects on exercise capacity 
are limited.
Longer-acting bronchodilators play an important role in 
the long-term management of patients with COPD, improv-
ing airflow limitation, reducing dyspnea linked to moderate 
exercise intensities, reducing exacerbation frequency, and 
improving HRQoL. Whether this generally leads to an 
increase in daily physical activities is currently unclear. Fac-
tors other than drug therapy alone are undoubtedly important 
in obtaining significantly improved exercise tolerance from 
bronchodilators.
The improvements in exercise tolerance and dyspnea 
observed under clinical trial conditions with some broncho-
dilators may impact on the everyday circumstances of COPD 
patients, reversing the vicious circle of chronic inactivity and 
muscle deconditioning, and leading to sustained improve-
ments in HRQoL.
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